Literature DB >> 6348063

Circadian variation of basal plasma growth hormone in man.

E C Drobny, K Amburn, G Baumann.   

Abstract

Human GH (hGH) circulating during periods of basal pituitary secretion is frequently undetectable in human plasma by RIA. Such basal periods predominate throughout most of the day. Knowledge of the concentration of basal hGH is important, since hGH plays a role in the homeostasis of several metabolic fuels and ions. We have used an immunoadsorbent technique to extract and concentrate hGH from large plasma samples before RIA in order to precisely measure basal hGH levels [immunoextracted RIA (IERIA)]. Twenty milliliters of blood were drawn from five normal volunteers every 2 h over a 24-h period. The obtained plasma (10-13 ml) was passed over an anti-hGH antibody Sepharose column. The column-bound hGH was eluted and measured by RIA. Recovery of hGH in the plasma extracts was measured using [131I]hGH as an internal standard. Recovery averaged 54 +/- 12% (mean +/- SD). Theoretically, the extraction procedure expanded the useful range of the RIA about 50-fold. In practice, the detection limit was 40 pg/ml plasma. Basal hGH (defined as less than 1 ng/ml by conventional RIA) was found to range from less than 40 to 746 pg/ml by IERIA. Above 2 ng/ml, conventional RIA and IERIA yielded comparable results (r = 0.92; P less than 0.001), but below 2 ng/ml, the two assays did not correlate (r = 0.01; P greater than 0.5). In general, conventional RIA overestimated plasma hGH in that range. As a result, the ratio between nocturnal and daytime hGH secretion, as assessed by IERIA, is higher than previously appreciated. We conclude that basal plasma hGH is highly variable below 1 ng/ml, and may on occasion be as low as less than 40 pg/ml. The episodic nature of hGH release appears to persist in the basal state. The conventional definition for basal hGH (less than 5 ng/ml) should probably be revised downward to less than 0.8 ng/ml.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6348063     DOI: 10.1210/jcem-57-3-524

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Inappropriate growth-hormone (GH) response to thyrotropin-releasing hormone (TRH) occurs infrequently in well-regulated diabetes mellitus.

Authors:  O Giampietro; M Ferdeghini; R Miccoli; G Gregori; G Penno; S Bertoli; R Navalesi
Journal:  Acta Diabetol Lat       Date:  1990 Apr-Jun

2.  Human growth hormone in urine: development of an ultrasensitive radiometric assay.

Authors:  T Erb; G Karolyi; A Pampalone; A N Eberle; J B Baumann; E Bürgisser; J Girard
Journal:  Experientia       Date:  1988-02-15

3.  Urinary growth hormone excretion rates in normal and acromegalic man: a critical appraisal of its potential clinical utility.

Authors:  L M Winer; M A Shaw; G Baumann
Journal:  J Endocrinol Invest       Date:  1989 Jul-Aug       Impact factor: 4.256

4.  Recent developments in the treatment of acromegaly.

Authors:  D K Lüdecke
Journal:  Neurosurg Rev       Date:  1985       Impact factor: 3.042

5.  The GH/IGF-1 Axis and Heart Failure.

Authors:  Graziella Castellano; Flora Affuso; Pasquale Di Conza; Serafino Fazio
Journal:  Curr Cardiol Rev       Date:  2009-08

Review 6.  Growth hormone secretagogues. Clinical experience and therapeutic potential.

Authors:  Z Laron
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

7.  Results of continuous long-term intravenous application of octreotide via an implantable pump system in acromegaly resistant to operative and X-ray therapy.

Authors:  G Hildebrandt; J Zierski; G Csecsei; H W Mueller; H Stracke
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.